Antigens, CD5
-
Subject Areas on Research
- A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.
- A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses.
- Analysis of the expression of CD5 by human B cells and correlation with functional activity.
- CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects.
- Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
- Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling.
- Composite lymphoma of mycosis fungoides and cutaneous small B-cell lymphoma in a 73-year-old male patient.
- Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature.
- Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.
- Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.
- Flow cytometric identification of intracellular antigens: detection of minimal residual leukemia.
- Human anti-pneumococcal polysaccharide antibodies are secreted by the CD5- B cell lineage.
- IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model.
- Mantle Cell Lymphoma With Mantle Zone Growth Pattern.
- Natural IgM is produced by CD5- plasma cells that occupy a distinct survival niche in bone marrow.
- Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
- Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
- Recent advances in de novo CD5+ diffuse large B cell lymphoma.
- Regulatory B cells as inhibitors of immune responses and inflammation.
- Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions.
- Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation.
- The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals.